CRP偺弞娐婍幘姵偵偍偗傞堄媊

CRP (C-reactive protein)偼丄媫惈婜墳摎抈敀偲偟偰屆偔偐傜抦傜傟偰偄傞丅墛徢偵傛傝丄寣拞擹搙偑寬峃帪偺悢昐攞偵忋徃偡傞偨傔椪彴偱墛徢儅乕僇乕偲偟偰昿梡偝傟偰偒偨丅嬤擭丄掅擹搙偱傕CRP傪崅姶搙偱應掕偱偒傞宯偑偱偒偨偙偲偵傛傝丄媫惈墛徢帪偺傛偆偵戝偒側擹搙忋徃偼側偔偰傕丄偛偔傢偢偐側CRP擹搙忋徃偑丄嘆彨棃偺嫊寣惈怱幘姵偺敪徢儕僗僋巜昗偵栶棫偮偙偲丄嘇媫惈姤徢岓孮敪徢偺恌抐巜昗偲側傞偙偲偑柧傜偐偲側偭偰偄傞丅偝傜偵嵟嬤丄嘊帯椕巜昗偲偟偰傕丄偦偺桳梡惈偑曬崘偝傟偨丅偡側傢偪丄Ridker傜偵傛傞JUPITER帋尡偱偼丄LDL僐儗僗僥儘乕儖偑惓忢抣偱偁傞偑丄CRP抣偑2 mg/L埲忋偺抣傪帵偡恖偵僗僞僠儞傪張曽偡傞偲丄怱寣娗僀儀儞僩偑44%尭彮偡傞偙偲丄偦偟偰丄僗僞僠儞偵傛傞LDL僐儗僗僥儘乕儖偺尭彮傛傝梊應偝傟傞岠壥傛傝傕偼傞偐偵戝偒偄僀儀儞僩尭彮棪偑尒傜傟偨偙偲偐傜丄僐儗僗僥儘乕儖掅壓嶌梡埲奜偺僗僞僠儞偺岠壥偑壛傢偭偰偄傞偙偲偑帵嵈偝傟偰偄傞(Ridker, P.M. et al. New Engl J Med 2008)丅偙偺傛偆偵崅姶搙應掕朄偵傛傝摼傜傟傞CRP寣拞擹搙偑嫊寣惈怱幘姵偺儅乕僇乕偲偟偰旕忢偵桳梡偱偁傞偙偲偑傢偐偭偰偒偨丅

CRP偼傕偲傕偲攛墛憃媴嬠 C懡摐懱寢崌抈敀偲偟偰摨掕偝傟丄嵶嬠丄曗懱場巕丄巰嵶朎丄巁壔LDL側偳條乆側暘巕偲寢崌偡傞婡擻暘巕偱偁傞丅忋弎偺傛偆偵CRP偑嫊寣惈怱幘姵偺儅乕僇乕偲偟偰旕忢偵桳梡側偙偲偐傜丄扨側傞儅乕僇乕偵偲偳傑傜偢丄摦柆峝壔傗嫊寣惈怱幘姵偺恑揥偵CRP偑愊嬌揑偵偐偐傢偭偰偄傞偺偱偼側偄偐偲偄偆帇揰偱偺尋媶偑恑傫偱偒偨丅摿偵寣娗撪旂嵶朎傊偺嶌梡偑拲栚偝傟偰偍傝丄CRP偵傛傝寣娗撪旂嵶朎偱妶惈巁慺庬嶻惗丄働儌僇僀儞傗嵶朎愙拝暘巕偺敪尰桿摫丄NO嶻惗尭彮側偳偺丄proatherogenic側曄壔偑婲偙傞偲偝傟偰偄傞丅偙傟傜偺斀墳偺懡偔偼Fc兞庴梕懱偱偁傞CD64丄CD32丄CD16傪夘偟偨斀墳偱偁傞偲尵傢傟偰偄傞丅

偙傟傜偺寣娗婡擻偲娭楢偟偨CRP偺惗棟妶惈偵偮偄偰偼憡斀偡傞榑愢傗寢壥傕偁偭偨丅榑憟偺堦場偼丄弮搙偺掅偄CRP偑梡偄傜傟偨偙偲偵傛傞嵞尰惈偺掅偄幚尡曬崘偵偁傞偑丄偙傟傜偺惗棟嶌梡傪斲掕偡傞媫愭朜偱偁偭偨Pepys傜帺恎傕丄儔僢僩偺怱嬝峓嵡儌僨儖偱CRP搳梌偑怱嬝峓嵡偺廳徢壔傪傑偹偒丄搳梌偟偨CRP偼怱憻慻怐撪偱曗懱宯偺妶惈壔傪桿摫偟偰偄傞偙偲傪帵偟偰偄傞(Pepys, M.B. et al. J Exp Med 1999)丅偝傜偵丄Pepys傜偼CRP偵寢崌偟CRP偺曗懱宯妶惈壔傪僽儘僢僋偡傞掅暘巕壔崌暔傪愝寁偟丄偦偺搳梌偵傛傝丄摨偠儔僢僩儌僨儖偱CRP偵傛傞怱嬝峓嵡埆壔傪偙偺掅暘巕壔崌暔偑梷惂偡傞偙偲傪帵偟偨(Pepys, M.B. et al. Nature 2006)丅傑偨丄CRP偺惗棟嶌梡傪扴偆庴梕懱偲偟偰曬崘偝傟偰偒偨Fc兞庴梕懱偺侾偮Fc兞RIIa庴梕懱偲CRP偺僼傽儈儕乕偱偁傞SAP偲偺暋崌懱偺寢徎峔憿傕柧傜偐偲側傝(Lu, J. et al. Nature 2008)丄CRP偺惗棟嶌梡偵偮偄偰偺媍榑傕惍棟偝傟偰偒偨偲峫偊傜傟傞丅

偦偙偱丄巹払偼寣娗撪旂婡擻忈奞偵偲傕偵娭梌偡傞LOX-1偲CRP偑壗傜偐偺宍偱憡屳嶌梡偡傞偙偲偵傛傝丄寣娗婡擻偵塭嬁傪梌偊傞壜擻惈偑側偄偐傪専摙偟偨丅

CRP偼寣娗撪旂偱偺LOX-1敪尰傪桿摫偡傞

CRP偱僸僩戝摦柆攟梴寣娗撪旂嵶朎傪CRP偱張抲偡傞偲丄LOX-1偺敪尰偼24帪娫屻傑偱憹壛偟丄CRP擹搙偑25 mg/L傑偱丄擹搙埶懚揑側桿摫偑傒傜傟偨(Li, L et al. Circ Res 2004)丅偙偺CRP偵傛傞LOX-1偺敪尰桿摫偼CRP庴梕懱偲偟偰抦傜傟傞Fc兞庴梕懱偺CD64偍傛傃CD32偺峈懱偱張抲偡傞偙偲偵傛傝梷惂偝傟傞偙偲偐傜丄偙傟傜偺庴梕懱傪夘偟偰偄傞偲峫偊傜傟偨丅CRP偼IL-6偺敪尰傕桿摫偟丄堦曽偱IL-6偼LOX-1偺敪尰傪桿摫偡傞丅偦偙偱丄CRP偵傛傞LOX-1桿摫偑IL-6傪夘偟偰偄傞壜擻惈傪峫偊丄峈IL-6峈懱偱張抲偡傞偲丄CRP偵傛傞LOX-1敪尰桿摫偼梷惂偝傟偨丅傑偨丄峈僄儞僪僙儕儞-1峈懱張抲偵傛偭偰傕梷惂偝傟傞偙偲偐傜丄僄儞僪僙儕儞暘斿傕LOX-1敪尰桿摫偵娭傢偭偰偄傞偲峫偊傜傟傞丅

CRP偱張抲偟偨撪旂嵶朎偼扨媴偺愙拝惈偑槾恑偟丄偙傟偼VCAM-1傗ICAM-1偺峈懱偵傛傝梷惂偝傟偢丄峈LOX-1峈懱偵傛傝梷惂偝傟傞偙偲偐傜丄庡偵忋弎偺LOX-1敪尰槾恑偵埶懚偟偨尰徾偲峫偊傜傟偨丅摨條偵丄CRP張抲偟偨撪旂嵶朎偼LOX-1偵埶懚偟偨昗幆巁壔LDL偺庢傝崬傒偑槾恑偟偰偄偨丅

偙傟傜偺偙偲偐傜丄CRP偵傛傞撪旂嵶朎婡擻曄壔偼丄LOX-1偺敪尰桿摫偲枾愙側娭學偑偁傞偙偲偑帵嵈偝傟偨丅

CRP偼LOX-1偵寢崌偡傞 

師偵丄LOX-1偲CRP偑捈愙憡屳嶌梡偡傞壜擻惈傪専摙偟偨丅寀岝昗幆偟偨CRP傪LOX-1敪尰嵶朎姅偵嶌梡偝偣傞偲LOX-1偺敪尰検偵埶懚偟偨寢崌偑娤嶡偝傟偨(Fujita, Y. et al. Clin Chem 2009)丅偦偟偰丄攟梴寣娗撪旂嵶朎偵懳偡傞CRP偺寢崌偑丄LOX-1偵懳偡傞siRNA張棟偵傛傝堦晹梷惂偝傟傞偙偲傕柧傜偐偲側偭偨丅傑偨丄柍嵶朎偺宯偱慻姺LOX-1抈敀傪屌憡壔偟偨僾儗乕僩偵旕昗幆CRP偑寢崌偟偨偙偲偐傜丄嵶朎偱娤嶡偝傟偨尰徾偑丄LOX-1偵傛偭偰偍偙傞娫愙揑側尰徾偱偼側偔丄CRP偲LOX-1偑捈愙寢崌偡傞偙偲偵傛傞偲尵偊傞丅

忋弎偺傛偆偵丄CRP偺庴梕懱偲偟偰Fc兞庴梕懱偑峀偔擣抦偝傟偰偄傞偺偱丄CRP偺寢崌傪Fc兞庴梕懱偲LOX-1偱斾妑偟偨丅LOX-1偱偼1-3 mg/L偺CRP擹搙偐傜寢崌偑娤嶡偝傟偨偺偵懳偟丄Fc兞庴梕懱偱偼傛傝崅偄擹搙偱寢崌偑娤嶡偝傟偨丅Fc兞庴梕懱偼丄墛徢嵶朎偵嫮偔敪尰偡傞偨傔丄墛徢帪偵斾妑揑崅擹搙偲側傞CRP偑敀寣媴偱嶌梡偡傞偲偒偵婡擻偡傞偺偵搒崌偑傛偄丅堦曽LOX-1偼丄Fc兞庴梕懱偺敪尰偑斾妑揑掅偔丄寣塼拞偵偁傞IgG偑CRP偲嫞崌偡傞偺偱Fc兞庴梕懱傊偼嶌梡偟偵偔偄撪旂嵶朎偺傛偆側嵶朎偱丄CRP偺嶌梡傪攠夘偡傞偺偵搒崌偑傛偄偲夝庍偡傞偙偲偑偱偒傞丅塽妛尋媶偱偼CRP偺怱寣娗昦敪徢儕僗僋昡壙偵偍偗傞cut-off抣偼1-3 mg/L偵捠忢愝掕偝傟傞偺偱丄偙偺儗儀儖偺CRP偱LOX-1傊偺寢崌偑傒傜傟傞偙偲偼丄怱寣娗昦敪徢儕僗僋偵懳偡傞塭嬁傪嵍塃偡傞壜擻惈傕帵嵈偡傞丅

LOX-1埲奜偺巁壔LDL庴梕懱傊偺CRP偺嶌梡傪専摙偟偰傒傞偲丄寢崌偱偼LOX-1偩偗偑嫮偔CRP傪寢崌偡傞偺偵懳偟丄庢傝崬傒偱偼LOX-1偩偗偱側偔SR-A偱傕寀岝昗幆CRP偑娤嶡偝傟偨丅懠偺CD36丄SR-BI丄CD68丄dectin-1傪敪尰偝偣偨COS-7嵶朎偱偼寀岝昗幆CRP偺庢傝崬傒偼傒傜傟側偐偭偨(Fujita, Y. et al. Clin Chem 2010)丅

SR-A偼丄儅僋儘僼傽乕僕偱婡擻偡傞偺偱丄THP-1嵶朎傪儅僋儘僼傽乕僕偵暘壔偝偣丄寀岝昗幆CRP偺庢傝崬傒幚尡傪峴偭偨丅偡傞偲儅僋儘僼傽乕僕偵暘壔偝偣偨THP-1嵶朎撪傊偺丄寀岝昗幆CRP偺庢傝崬傒偼丄SR-A偵懳偡傞siRNA張棟偵傛傝梷惂偝傟傞偙偲偑柧傜偐偲側偭偨丅儅僋儘僼傽乕僕偱偺SR-A傪夘偟偨CRP偺婡擻偼晄柧偩偑丄昦尨懱傪寢崌偟偨CRP傪婷怘偡傞偙偲偵傛傝惗懱杊屼偵摥偄偰偄傞偺偐傕偟傟側偄丅

CRP偼LOX-1偵埶懚偟偰曗懱妶惈壔傪婲偙偡 

CRP偑LOX-1偲寢崌偡傞偙偲偺惗棟揑堄媊傪専徹偡傞偨傔偵丄CRP偑惗懱撪偱婲偙偡斀墳偵偮偄偰偺夝愅傪峴偭偨丅崅寣埑儔僢僩偺SHRSP偼LOX-1敪尰偑嬌傔偰崅偄偙偲偐傜丄SHRSP偲惓忢寣埑儔僢僩偱LOX-1敪尰傕彮側偄WKY傪斾妑偟偰幚尡傪峴偭偨丅CRP傪旂撪拲幩偟丄惷拲偟偨僄僶儞僗僽儖乕偺楻弌偵傛傝寣娗摟夁惈偺昡壙傪峴偆偲丄SHRSP偱偼WKY偲斾妑偟桳堄偵嫮偄CRP偵傛傞寣娗摟夁惈偺槾恑偑傒傜傟偨丅偙偺嵺丄VEGF偵傛偭偰婲偙傞寣娗摟夁惈槾恑偵偼堘偄偼尒傜傟側偐偭偨丅偙偺CRP偵傛傝SHRSP偱庝婲偝傟傞寣娗摟夁惈槾恑偼峈LOX-1峈懱傪摨帪搳梌偵偡傞偙偲偵傛傝梷惂偝傟丄LOX-1偲CRP偺憡屳嶌梡偵傛傞傕偺偱偁傞偙偲偑帵嵈偝傟偨丅偝傜偵丄SHRSP偺CRP拲幩晹埵偺旂晢慻怐傪娤嶡偟偰傒傞偲丄曗懱宯妶惈壔丄敀寣媴偺怹弫偑尒傜傟丄偦傟傜偼峈LOX-1峈懱傪摨帪搳梌偟偨応崌偵偼桳堄偵梷惂偝傟偰偄偨(Fujita, Y. et al. Clin Chem 2011)丅

偦偙偱in vitro偺幚尡傪峴偄丄LOX-1抈敀傪屌憡壔偟偨僾儗乕僩偵CRP偲寣惔傪嶌梡偝偣傞偲曗懱宯妶惈壔偑婲偙傞偙偲丄偝傜偵丄偙傟偑C1q偵埶懚偡傞曗懱宯屆揟宱楬偺妶惈壔偵傛傞偙偲傪柧傜偐偵偟偨丅偙傟傜偺偙偲偐傜in vivo偱偺CRP偵傛傞曗懱宯妶惈壔偼LOX-1偵傛傝懀恑偝傟偨偲峫偊傜傟偨丅傑偨丄CRP偺婡擻揑峔憿偼C1q偑寢崌偡傞A face偲僼僅僗僼僅僐儕儞偑寢崌偡傞B face偐傜側傞偑丄LOX-1偲CRP偺寢崌偑僼僅僗僼僅僐儕儞偺揧壛偵傛傝梷惂偝傟傞偙偲偐傜丄LOX-1偲CRP偺B face偑寢崌偟丄斀懳懁偺A face偱C1q傪夘偟偨曗懱妶惈壔傪堷偒婲偙偟偰偄傞偲峫偊傜傟偨丅

CRP偵傛傞寣娗撪旂偺斀墳偑LOX-1偵傛傝堷偒婲偙偝傟傞曄壔偲傛偔帡偰偄傞偨傔丄巹払偼CRP偲LOX-1偺娭學偵拝栚偟偨丅CRP偼撪旂嵶朎偱LOX-1偺敪尰桿摫傪堷偒婲偙偟丄LOX-1偵傛傞扨媴愙拝傗巁壔LDL寢崌傪懀恑偡傞丅堦曽偱丄LOX-1偼CRP傪寢崌偟偰丄CRP偵傛傞曗懱宯妶惈壔傪懀恑偡傞偲偲傕偵LOX-1偺敪尰晹埵偵嬊強壔偡傞偲峫偊傜傟傞丅

偙偺傛偆偵嫊寣惈怱幘姵偺婋尟場巕丄巁壔LDL偺庴梕懱偱偁傞LOX-1偑丄撈棫偟偨婋尟場巕偱偁傞CRP偺庴梕懱偲偟偰傕摥偒丄CRP偲嫤挷偟偰寣娗摟夁惈槾恑傗曗懱宯妶惈壔傪堷偒婲偙偡偙偲偑柧傜偐偲側偭偨丅

嶲峫暥專

Ridker, P.M. et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207, 2008.

Pepys, M.B. et al.: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190:1733-1740, 1999

Pepys, M.B. et al.: Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440:1217-1221, 2006.

Lu, J. et al.: Structural recognition and functional activation of Fc兞R by innate pentraxins. Nature 456, 989-992, 2008.

Li, L., Roumeliotis, N., Sawamura, T. and Renier, G.: C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 95:877-883, 2004.

Fujita, Y., Kakino, A., Nishimichi, N., Yamaguchi, S., Sato, Y., Machida, S., Cominacini, L., Delneste, Y., Matsuda, H. and Sawamura, T.: Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 55:285-294, 2009.

Fujita, Y., Kakino, A., Harada-Shiba, M., Sato, Y., Otsui, K., Yoshimoto, R. and Sawamura, T.: C-reactive protein uptake by macrophage cell line via class-A scavenger receptor. Clin Chem 56:478-481, 2010.

Fujita, Y., Yamaguchi, S., Kakino, A., Iwamoto, S., Yoshimoto, R. and Sawamura, T.: Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation. Clin Chem 57:1398-1405, 2011.

丂丂丂丂丂丂

尋媶奣梫
巁壔LDL庴梕懱LOX-1偺敪尒
LOX-1偲嵶朎偲偺憡屳嶌梡偐傜嵶朎愙拝丒墛徢傊
LOX-1偵寢崌偡傞撪場惈偺儕億抈敀幙
LOX-1僽儘僢僇乕偺奐敪
LOX-1傪梡偄偨恌抐媄弍偺奐敪